Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Research and Development Grants

Université de Montréal

$46,890.00

C-N bonds synthesis towards biologically active molecules

EF 2010-11

Résumé
The global scientific objective of this project is to develop new tools for the elaboration of chiral nitrogen-containing molecules. Such types of molecules are ubiquitous components of biologically active molecules and thus of primary importance for the pharmaceutical industry. Our specific goal is to develop more efficient stereoselective synthetic strategies to streamline the synthesis of chiral nitrogen-containing molecules as single enantiomers. Numerous methods to produce C-N bonds have been reported previously. However improvements of the existing technologies as well as developments of novel approaches are still highly desirable, in particular for the synthesis of chiral amines, due to their importance as pharmacologic building blocks. The current most efficient methods for the synthesis of chiral amines are based on functional group transformations. An alternative, original and modern approach is to functionalize carbon frameworks, using metal nitrenes capable of performing C H insertions with alkanes and aziridination reactions with alkenes. Such a strategy will be highly desirable in particular if it can be performed with good stereoselectivities to produce chiral building blocks with high level of stereochemical induction. More importantly, the application of these technologies to the synthesis of molecules possessing useful pharmacological properties is instrumental to establish the scope of these methods. Giving the importance of nitrogen-containing molecules in pharmaceutical sciences, innovation in the stereoselective synthesis of these products will be greatly beneficial for a health care devoted company, such as Janssen-Ortho Inc, a member of the Johnson & Johnson worldwide family of companies. The success of such a company is directly related to its capability of producing organic molecules with high efficiency. If successful, this proposal will provide Janssen-Ortho Inc. not only novel methods to synthesize chiral nitrogen compounds, but also novel synthetic ways to streamline the elaboration of complex biologically active molecules.
Programme
Collaborative Research and Development Grants
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
396292-2010
Name nom
Lebel, Hélène
Department département
Chimie
Organization id
63
Institution établissement
Université de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2010
Competition year année de concours
2010
Award amount
46890
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3703
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Organic syntheses
Research subject fr
Synthèses organiques
Partie
1
Nb partie
2
Application title
C-N bonds synthesis towards biologically active molecules
Keyword
NSERC
Application summary
The global scientific objective of this project is to develop new tools for the elaboration of chiral nitrogen-containing molecules. Such types of molecules are ubiquitous components of biologically active molecules and thus of primary importance for the pharmaceutical industry. Our specific goal is to develop more efficient stereoselective synthetic strategies to streamline the synthesis of chiral nitrogen-containing molecules as single enantiomers. Numerous methods to produce C-N bonds have been reported previously. However improvements of the existing technologies as well as developments of novel approaches are still highly desirable, in particular for the synthesis of chiral amines, due to their importance as pharmacologic building blocks. The current most efficient methods for the synthesis of chiral amines are based on functional group transformations. An alternative, original and modern approach is to functionalize carbon frameworks, using metal nitrenes capable of performing C H insertions with alkanes and aziridination reactions with alkenes. Such a strategy will be highly desirable in particular if it can be performed with good stereoselectivities to produce chiral building blocks with high level of stereochemical induction. More importantly, the application of these technologies to the synthesis of molecules possessing useful pharmacological properties is instrumental to establish the scope of these methods. Giving the importance of nitrogen-containing molecules in pharmaceutical sciences, innovation in the stereoselective synthesis of these products will be greatly beneficial for a health care devoted company, such as Janssen-Ortho Inc, a member of the Johnson & Johnson worldwide family of companies. The success of such a company is directly related to its capability of producing organic molecules with high efficiency. If successful, this proposal will provide Janssen-Ortho Inc. not only novel methods to synthesize chiral nitrogen compounds, but also novel synthetic ways to streamline the elaboration of complex biologically active molecules.